Clinical trials: Opiate Use Disorder
Substance-related Disorders
PHAST: Physical Activity in Substitution Therapy
The aim is to examine the effect of exercise (EX) training on individuals currently receiving ST - either opiate replacement therapy (ORT) or heroin-assisted treatment (HAT) - for their opiate dependence.
- Trial name
- PHAST (NCT02309021)
- Testing
- Sport, Non-sport activities
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University Hospital, Basel, Switzerland
Accidental Overdose of Opiate
Remote Intervention to Prevent Overdose
This Type 1 hybrid effectiveness-implementation randomized controlled trial, A Remote Intervention to Prevent Overdose among People who Use Stimulants and/or Opioids, aims to address the United States opioid crisis driven by…
- Trial name
- NCT07128485
- Testing
- Overdose prevention resources, Overdose prevention education
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Alabama at Birmingham
Opiate Addiction, Refractory Pain
Buprenorphine as a Treatment in Opiate Dependent Pain Patients
This study is designed to determine if different doses of buprenorphine (either tapering doses or steady doses) are effective in managing chronic, non-cancer pain in individuals who also are addicted to opiate pain medicines.
- Trial name
- NCT00552578
- Testing
- buprenorphine/naloxone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- State University of New York at Buffalo
Substance Use Disorders, Substance Abuse
Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone
This is an open-label, single center study of The Bridge in patients with sustained remission of opiate dependence on established, low-dose MAT with buprenorphine. A fixed number of patients will be admitted to the study.
- Conditions
- Substance Use Disorders, Substance Abuse, Substance Use, Substance Dependence
- Trial name
- NCT03762798
- Testing
- The Bridge
- Where
- United States
- Sponsor
- The Cleveland Clinic
Opioid Use Disorder, Opioid Abuse and Addiction
GLP-1R Agonist Treatment for Opioid Use Disorder
The goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment.
- Conditions
- Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders
- Trial name
- NCT06548490
- Testing
- Semaglutide Pen Injector
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Milton S. Hershey Medical Center
Mental and Behavioral Disorders Due to Use of Cocaine: Harmful Use, Opiate Addiction
Recovery Housing and Drug Abuse Treatment Outcome
Reinforcement-Based Therapy (RBT) is an intensive outpatient substance abuse treatment that includes relapse prevention skills training, goal setting, help with finding employment and abstinence-contingent rent payment for…
- Trial name
- NCT03278496
- Testing
- Recovery Housing plus Counseling, Usual Care Referral, Recovery Housing Only
- Where
- United States
- Volunteers
- 243 people
- Sponsor
- Johns Hopkins University
Opioid-Related Disorders, Drug Addiction
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
This is a sub-study of NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs; Unique protocol ID: 2019-0429-1).
- Conditions
- Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse
- Trial name
- MOMs-INO (NCT03911739)
- Testing
- Buprenorphine Injection, Buprenorphine Sublingual Product
- Where
- 10 sites in United States
- Volunteers
- 71 people
- Sponsor
- T. John Winhusen, PhD
Chronic Pain, Pain
A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain
This Phase 2 study will evaluate whether multiple doses of cebranopadol suppress opioid withdrawal signs and symptoms compared with placebo in adults with chronic pain who are physically dependent on prescribed opioids.
- Conditions
- Chronic Pain, Pain, Opioid Withdrawal (Disorder), Opioid Use Disorder
- Trial name
- NCT07874620
- Testing
- Cebranopadol
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Adneuris Therapeutics, Inc.
Obesity
Dexmedetomidine to Treat Bariatric Surgery-associated Pain
Obesity represents one of the most important public health issues according to the World Health Organization and it has reached epidemic proportions globally.
- Trial name
- NCT02880540
- Testing
- Fentanyl, Morphine, Dexmedetomidine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Janelle Vaughns
Medication Abuse, Harm Reduction
Evaluation of Clinical Decision Support in Opioid Tapering
The 2022 Center for Disease Control and Prevention (CDC) clinical practice guideline for prescribing opioids for pain recommends that when tapering a patient's opioid dose, doses should be decreased at a slow rate to reduce the…
- Conditions
- Medication Abuse, Harm Reduction, Opioid Use Disorder, Opioid Prescribing
- Trial name
- NCT06527079
- Testing
- Observational study without a prospective intervention
- Volunteers
- 200,000 people
- Sponsor
- University of Colorado, Denver
Opioid-Use Disorder (OUD)
SafetyNet Program for Opioid Use Disorder (OUD)
The principal aim of this study is to determine whether a novel biopsychosocial intervention following opioid overdose (OD) affects 1) the frequency of secondary opioid OD events and 2) the proportion of individuals who remain…
- Trial name
- NCT04253782
- Testing
- Team Intervention
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Yale University
Opioid-use Disorder, Amphetamine Use Disorders
Neurocognitive Empowerment for Addiction Treatment (NEAT) in Opioid Use Disorder and Amphetamine Use Disorder
Chronic drug addiction is not only associated with increased mental health symptoms, such as anxiety and depression, but also with brain (neural and cognitive) deficits.
- Trial name
- NEAT (NCT03922646)
- Testing
- Neurocognitive Empowerment for Addiction Treatment (NEAT), Active Control
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Laureate Institute for Brain Research, Inc.
Healthy
The Effects of ∆-9-THC and Naloxone in Humans
The purpose of this project is to examine the effects of mu-opiate antagonism on the rewarding and reinforcing effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive ingredient of cannabis.
- Trial name
- NCT01591629
- Testing
- Naloxone, Delta-9-THC
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Yale University
Opioid Use Disorder
Methadone Rapid Restart
The usual treatment for opioid use disorder (OUD) is opioid agonist therapy (OAT) with either methadone or buprenorphine. These treatments are well-established, reduce the risk of fatal overdoses, and are considered the standard…
- Trial name
- NCT07546396
- Testing
- Methadone
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Pouya Azar
Opioid-Related Disorders, HIV Infections
Buprenorphine and Integrated HIV Care Evaluation
The purpose of this study is to assess the feasibility, cost and effectiveness of interventions designed to integrate buprenorphine treatment for opioid dependence into HIV primary care in ten HIV care centers in the U.S.
- Conditions
- Opioid-Related Disorders, HIV Infections, AIDS
- Trial name
- NCT00124358
- Testing
- Buprenorphine, Integrated HIV care and office-based opioid dependence treatment
- Where
- 10 sites in United States
- Volunteers
- 1,350 people
- Sponsor
- The New York Academy of Medicine
Opioid Overdose, Opioid-use Disorder
User Acceptability of a Device-Based Opioid Overdose Intervention
This pilot study evaluates the needs of opioid users for a device-based intervention for opioid overdoses. The results of this one-time short questionnaire will inform development of a novel naloxone delivery device.
- Conditions
- Opioid Overdose, Opioid-use Disorder, Substance Use Disorders
- Trial name
- NCT04530591
- Testing
- Survey, Interview
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- University of Pennsylvania
Opioid-Use Disorder, Opioid Overdose
Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
This pilot study will evaluate the feasibility and clinical utility of extended-release injectable buprenorphine (XR-BUP) for the treatment of opioid use disorder (OUD) among individuals at high-risk for overdose (OD).
- Trial name
- FASTER-BUP (NCT04815590)
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- BC Centre on Substance Use
Opioid Withdrawal, Opioid Use Disorder (OUD)
Sparrow Link Neuromodulation Device for Opioid Withdrawal Management in Hospitalized Adults With Opioid Use Disorder
This study is evaluating the Sparrow Link, a wearable device that delivers gentle electrical signals to nerves in the outer ear (a technique known as transcutaneous auricular neurostimulation, or tAN).
- Trial name
- NCT07079826
- Testing
- Sparrow Link (Active tAN)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Payel Roy
Opioid-use Disorder, HIV-1-infection
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
HIV infection, as well as exposure to opioids (including heroin), are associated with systemic immune activation including increased microbial translocation from the gut.
- Conditions
- Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation
- Trial name
- AMOHI-1 (NCT04480554)
- Testing
- Methadone, Buprenorphine/naloxone, XR-Naltrexone
- Where
- 2 sites in United States, Vietnam
- Volunteers
- 78 people
- Sponsor
- University of Pennsylvania
Opiate Addiction
Onsite Buprenorphine Treatment at Syringe Exchange Programs
This trial will recruit syringe exchange participants with opioid use disorder in New York City and test whether starting buprenorphine treatment at the syringe exchange program is more effective than referral to a community…
- Trial name
- O-BMT (NCT03150173)
- Testing
- Onsite treatment, Enhanced referral, Buprenorphine
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- Montefiore Medical Center